Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 5/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | XDH | P47989 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.37 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31063495 | 1.00 | ERN1 (0.44) | ERN1LCKXDHTRPA1ALDH1A3 | |
| SCHEMBL373244 | 0.84 | ERN1 (0.52) | ERN1LCKTRPA1PTPN2PTPN1 | |
| SCHEMBL1922945 | 0.84 | ERN1 (0.52) | ERN1XDH | |
| SCHEMBL29396510 | 0.83 | EGFR (0.50) | ERN1XDHTRPA1PTPN1EGFR | |
| SCHEMBL1005213 | 0.83 | EGFR (0.50) | ERN1XDHTRPA1PTPN1EGFR | |
| SCHEMBL30822600 | 0.80 | XDH (0.52) | ERN1XDH | |
| SCHEMBL1056033 | 0.80 | XDH (0.52) | ERN1XDH | |
| SCHEMBL19655038 | 0.79 | TRPA1 (0.38) | ERN1LCKTRPA1PTPN2PTPN1 | |
| SCHEMBL19748916 | 0.78 | ALDH1A1 (0.35) | TRPA1ALDH1A3 | |
| SCHEMBL29655021 | 0.78 | ALDH1A1 (0.35) | TRPA1ALDH1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4665339-A1 | INHIBITING ALPHA V BETA 8 INTEGRIN | Morphic Therapeutic, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| EP-4665458-A1 | INHIBITING ALPHA V BETA8 INTEGRIN | Morphic Therapeutic, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| WO-2024173570-A1 | INHIBITING αvβ8 INTEGRIN | MORPHIC THERAPEUTIC, INC. (US) | 2024-08-22 | — | — | WO | disclosed |
| WO-2024173572-A1 | INHIBITING α vβ8 INTEGRIN | MORPHIC THERAPEUTIC, INC. (US) | 2024-08-22 | — | — | WO | disclosed |
| CN-116535361-A | Substituted hydroxypyrimidine xanthine oxidase inhibitor and preparation method and pharmaceutical application thereof | 中国医学科学院药物研究所 | 2023-08-04 | — | — | CN | disclosed |
| US-20230141569-A1 | FLUORESCENT DYE, AND PREPARATION METHOD AND USES THEREOF | FLUORESCENCE DIAGNOSIS (SHANGHAI) BIOTECH COMPANY LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| US-20230141569-A1 | FLUORESCENT DYE, AND PREPARATION METHOD AND USES THEREOF | FLUORESCENCE DIAGNOSIS (SHANGHAI) BIOTECH COMPANY LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| US-20230133910-A1 | NEW METHOD FOR DETECTING AND QUANTIFYING RNA | EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2023-05-04 | — | — | US | disclosed |
| US-20230133910-A1 | NEW METHOD FOR DETECTING AND QUANTIFYING RNA | EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2023-05-04 | — | — | US | disclosed |
| EP-4129985-A1 | FLUORESCENT DYE, PREPARATION METHOD THEREFOR AND USE THEREOF | Fluorescence Diagnosis (shanghai) Biotech Company Ltd. (CN) | 2023-02-08 | — | — | EP | disclosed |
| US-20120208817-A1 | Novel Dihydropyrimidin-2(1H)-one Compounds as S-Nitrosoglutathione Reductase Inhibitors | N30 PHARMACEUTICALS, LLC (US) | 2012-08-16 | — | — | US | disclosed |
| EP-2480086-A1 | NOVEL DIHYDROPYRIMIDIN-2(1H)-ONE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | N30 Pharmaceuticals, LLC (US) | 2012-08-01 | — | — | EP | disclosed |
| WO-2011038204-A1 | NOVEL DIHYDROPYRIMIDIN-2(1H)-ONE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | N30 PHARMACEUTICALS, LLC (US) | 2011-03-31 | — | — | WO | disclosed |
| WO-2011002814-A2 | BIARYL OXYACETIC ACID COMPOUNDS | LIGAND PHARMACEUTICALS INC. (US) | 2011-01-06 | — | — | WO | disclosed |
| WO-2011002814-A2 | BIARYL OXYACETIC ACID COMPOUNDS | LIGAND PHARMACEUTICALS INC. (US) | 2011-01-06 | — | — | WO | disclosed |
| WO-2010102154-A2 | BIARYL OXYACETIC ACID COMPOUNDS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2010-09-10 | — | — | WO | disclosed |
| WO-2010102154-A2 | BIARYL OXYACETIC ACID COMPOUNDS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2010-09-10 | — | — | WO | disclosed |
| US-6090834-A | ANALGESICS; RHEUMATIC DISORDERS; SKIN DISORDERS; GASTROINTESTINAL DISORDERS | G.D. SEARLE & CO. (US) | 2000-07-18 | — | — | US | disclosed |
| EP-0825989-A1 | SUBSTITUTED OXAZOLES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1998-03-04 | — | — | EP | disclosed |
| WO-1996036617-A1 | SUBSTITUTED OXAZOLES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208817-A1 | Novel Dihydropyrimidin-2(1H)-one Compounds as S-Nitrosoglutathione Reductase Inhibitors | QDPR, GSR, CBR1 | ERN1 3139/4885LCK 4349/4885XDH 258/4885 |
| US-20230141569-A1 | FLUORESCENT DYE, AND PREPARATION METHOD AND USES THEREOF | DNASE1, DNA2, RNGTT | ERN1 534/4885LCK 4099/4885XDH 1334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.